FORMULATION AND EVALUATION OF GASTRORETENTIVE FLOATING TABLET OF LISINOPRIL

The present work involves the design, development and in-vitro evaluation of Lisinopril floating pulsatile release tablet, in which the core tablets are rapid release formulation which is coated with hydrophilic polymers such as HPMC E15, HPMC K15M, HPMC K4M, Xanthan gum individually and in combination. FPRT was designed for the treatment of morning surge of Hypertension The rapid release core tablets of Lisinopril were formulated with various concentrations of SSG (2%, 3% and 4%), CCS (1%, 1.5% and 2%) and Crospovidone (2 %, 3.5% and 5%) by direct compression. The in-vitro dissolution studies of the formulated Lisinopril Core tablets were performed using USP type-II dissolution apparatus. From the formulated batches, the formulation F3 released the drug very quickly (within 4 minutes) when compared to other formulations. Based on the Disintegration and in-vitro release studies of Lisinopril rapid release core tablets, formulation F3 was optimized and selected for Press coating. The formulated Lisinopril FPRTs were found to be within limits with respect to Weight uniformity, Hardness, Thickness, Diameter and Friability. The drug content of the Lisinopril FPRTs were estimated and found to be within Pharmacopoeial limits. The formulated Lisinopril FPRTs were found to be within limits with respect to Weight uniformity, Hardness, Thickness, Diameter and Friability. The drug content of the Lisinopril FPRTs were estimated and found to be within Pharmacopoeial limits.